Drugs / emtricitabine/tenofovir disoproxil fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03547908 Comparator | May 2018 → Feb 2022 | — | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | emtricitabine/tenofovir disoproxil fumarate | “The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus...” NCT03547908 ↗ |
| Known as | F/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03547908 ↗ |